Completed × Squamous Cell Carcinoma of Head and Neck × Gynecologic × Clear all
NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Completed
145 enrolled 47 charts
NCT04068896 2025-05-29

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NGM Biopharmaceuticals, Inc

Phase 1/2 Completed
89 enrolled 21 charts
NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Cyteir Therapeutics, Inc.

Phase 1/2 Completed
169 enrolled
NCT03752398 2024-07-05

DUET-3

Xencor, Inc.

Phase 1 Completed
198 enrolled
NCT03454451 2023-12-21

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Corvus Pharmaceuticals, Inc.

Phase 1 Completed
117 enrolled
NCT03849469 2023-03-30

DUET-4

Xencor, Inc.

Phase 1 Completed
78 enrolled
NCT03517488 2022-12-01

DUET-2

Xencor, Inc.

Phase 1 Completed
150 enrolled
NCT03241173 2022-09-27

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Completed
52 enrolled 25 charts
NCT02315066 2022-04-21

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Pfizer

Phase 1 Completed
174 enrolled 68 charts
NCT03652077 2021-11-15

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Incyte Corporation

Phase 1 Completed
40 enrolled
NCT03538028 2020-10-30

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Incyte Corporation

Phase 1 Completed
22 enrolled
NCT00003657 2017-01-20

High-dose ICE With Amifostine

Dana-Farber Cancer Institute

Phase 2 Completed
24 enrolled
NCT00900302 2016-02-10

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

OHSU Knight Cancer Institute

Completed
98 enrolled
NCT00006981 2015-04-30

Immunotoxin Therapy in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00066651 2015-04-30

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
NCT00538850 2014-03-05

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

INSYS Therapeutics Inc

Phase 3 Completed
130 enrolled 9 charts
NCT00526149 2013-10-07

BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
76 enrolled
NCT00031681 2013-09-30

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

National Cancer Institute (NCI)

Phase 1 Completed
41 enrolled
NCT00014456 2013-08-28

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

Dartmouth-Hitchcock Medical Center

Phase 1 Completed
35 enrolled
NCT00003103 2013-07-03

Chemotherapy in Treating Patients With Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
57 enrolled
NCT00004065 2013-06-24

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00019331 2013-06-20

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
NCT00045006 2013-05-30

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00089362 2013-04-10

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00004074 2013-02-28

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled